Screener
Rapport Therapeutics, Inc. RAPP Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Rapport Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Rapport Therapeutics, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210355
| Line item | For the three monthsended March 31, 2026 | For the three monthsended March 31, 2025 |
|---|---|---|
| Proceeds from exercise of stock options | 809 | 6 |
| Repurchase of unvested restricted common stock | (5) | (1) |
| Net cash provided by financing activities | 531 | 5 |
| Net increase in cash, cash equivalents, and restricted cash | 25,411 | 799 |
| Cash, cash equivalents, and restricted cash at beginning of period | 52,750 | 56,910 |
| Cash, cash equivalents, and restricted cash at end of period | $78,161 | $57,709 |
| Supplemental cash flow information: | ||
| Supplemental disclosure for noncash investing and financing activities: |
Item 1. Financial Statements.
FAQ
- What is Rapport Therapeutics, Inc.'s net change in cash?
- Rapport Therapeutics, Inc. (RAPP) reported net change in cash of $25.41M in Q1 2026.
- How has Rapport Therapeutics, Inc.'s net change in cash changed year-over-year?
- Rapport Therapeutics, Inc.'s net change in cash increased by 3080.4% year-over-year, from $799K to $25.41M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Rapport Therapeutics, Inc.'s net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude